Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 11.450-11.450 for the period, compared to the consensus estimate of 11.330. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CRL shares. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Barclays increased their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a research note on Friday. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Finally, Evercore set a $330.00 target price on shares of Charles River Laboratories International in a research note on Friday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $287.06.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $292.49 on Friday. The company has a market cap of $13.96 billion, a PE ratio of -60.31, a P/E/G ratio of 2.86 and a beta of 1.40. The company has a fifty day moving average price of $270.45 and a two-hundred day moving average price of $213.04. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a 12 month low of $145.32 and a 12 month high of $303.30.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the previous year, the firm earned $3.12 earnings per share. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts expect that Charles River Laboratories International will post 11.45 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Shannon Parisotto sold 2,039 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $294.12, for a total transaction of $599,710.68. Following the sale, the executive vice president owned 4,807 shares in the company, valued at $1,413,834.84. This represents a 29.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares in the company, valued at $7,788,017.16. This represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is owned by company insiders.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised their price targets. Royal Bank of Canada lifted its target from $282 to $322 and maintained an “outperform” rating, while Robert W. Baird raised its target from $291 to $334 and also rated CRL “outperform.” These revisions imply roughly 10% to 14% additional upside from the referenced price.
• Positive Sentiment: Investor Day provided stronger long-term growth visibility. Charles River reaffirmed its fiscal 2026 revenue outlook at approximately $3.9 billion and raised EPS guidance to $11.45, above the $11.33 analyst consensus. The company also introduced 2030 growth targets, helping drive a recent rally in the stock. Charles River Laboratories Stock Rises 6% After Unveiling 2030 Growth Targets
• Positive Sentiment: Investor reaction has been favorable. Reports indicated CRL rose about 5% to 6% following the company’s Investor Day presentation, reflecting investor confidence in the updated 2026 outlook and longer-term targets. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Neutral Sentiment: Mizuho raised its target but remained cautious. The firm increased its target from $264 to $295 but kept a “neutral” rating, suggesting limited upside from the referenced price and a more balanced risk-reward assessment.
• Negative Sentiment: Some of the good news may already be priced in. An investor analysis characterized the Investor Day as positive but argued that the improved outlook is fully reflected in CRL’s valuation. This may explain why the stock has decreased modestly despite favorable announcements. Charles River Laboratories: Positive Investor Day Is Fully Priced In

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.